pone.0258614.g002.tif (427.56 kB)

Subject disposition.

Download (427.56 kB)
posted on 2022-06-14, 17:32 authored by Benjamin Rix Brooks, Terry Heiman-Patterson, Martina Wiedau-Pazos, Shawn Liu, Jeffrey Zhang, Stephen Apple

The diagram shows subject disposition for the various stages of Study 19 and reasons for discontinuation. Note that for the overall study, subjects who returned for follow-up through cycle 11 were considered to have “completed” the study; however, a total of 5 subjects did not have data available for cycle 12 (2 subjects in the edaravone-edaravone group and 3 in the placebo-edaravone group, as indicated in the figure) and those subjects were excluded from the statistical analyses presented in this study. Adapted with permission [19]. ALS, amyotrophic lateral sclerosis; FVC, forced vital capacity (% of predicted); PaCO2, partial pressure of carbon dioxide in arterial blood.